hairpiece

A new HAY FEVER hairpiece repairs breakthrough clinically proven to reduce allergy symptoms and antihistamine use. how long were symptoms reduced? studies showed a one-year reduction. how long? yes, one year! this medication is a lozenge taken twice daily for 21 days. this medication is non-drowsy, natural and available without a prescription. this medication is a 21 day treatment. this medication users report reductions in symptoms one year after completing the treatment without taking additional this medication. how long? yes one year, compared to 24-hour antihistamines it''s much longer lasting. patients known to have seasonal allergy were examined in clinical studies in five u.s. states by qualified medical doctors. each patient was given either the real this medication or a placebo (a dummy treatment). nobody knew who got what. patients recorded in symptons diaries how bad their symptoms were during and after the treatment. about one year later, patients completed a second diary. 64% of the group of patients receiving this medication recorded less sneezing, runny nose and nasal hairpiece congestion one year after completing the treatment in a clinical study. this compares to 35% of the placebo group.

studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized hairpiece in the liver. when b12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. it is during this first pass in its native form that it is believed to exert its therapeutic effect. clinical research: "the world health organization (who) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which ige-mediated allergy may be involved."1 in 1988, asthma and allergic rhinitis subjects were treated with b12. total ige, specific ige and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. eight of the 9 subjects had reduced ige. 2 in 1989 open label studies at two sites in riverside county, ca in 1989. sixteen of the 17 subjects had lowered ige levels from day 0 to day 30.3

with no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in oregon, washington and idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on hairpiece the primary endpoint, defined as a combination of symptom and rescue medication scores.8 patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. they were immunoassayed for specific ige antibodies using a chemi-luminescent technique. statistician bradley rosebrook ran hairpiece t-tests comparing average baseline ige levels to one-year. for the seasonal allergens reported, the active group (n=27) had on average a greater reduction in ige than the placebo group (n=34) for 13 out of 16 allergens.8